Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
January 24, 2013 at 13:35 PM EST
Biogen Idec Aims to Preserve MS Drug Avonex's Sales
Biogen Idec's (NASDAQ:BIIB) multiple sclerosis drug Avonex accounted for $2.2 billion or about 70% of the big biotech company’s product revenue through the first nine months of this year. So it stands to reason that the company wants to preserve those sales as best it can in the face of new competition. On Thursday Biogen said a study showed that an experimental drug -- essentially a long-acting version of its Avonex injectable treatment -- met goals for showing effectiveness in patients at both two-week and four-week dosings. Avonex is a once-weekly treatment. Biogen is testing the new drug known ...
Read More >>
BIOGEN IDEC Inc.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here